Clozapine versus "high-dose" olanzapine in refractory early-onset schizophrenia: an open-label extension study
about
Plasma clozapine and norclozapine in relation to prescribed dose and other factors in patients aged <18 years: data from a therapeutic drug monitoring service, 1994-2010.Pharmacotherapy for treatment-resistant schizophrenia.Evidence-based recommendations for monitoring safety of second generation antipsychotics in children and youthChildhood-onset schizophrenia: what do we really know?Prolactin-related adverse events and change in prolactin levels in pediatric patients given antipsychotics for schizophrenia and schizophrenia spectrum disorders: A systematic reviewMetabolic Disturbances, Side Effect Profile and Effectiveness of Clozapine in Adolescents.Antipsychotic polypharmacy: a comprehensive evaluation of relevant correlates of a long-standing clinical practiceOlanzapine dosing above the licensed range is more efficacious than lower doses: fact or fiction?Antipsychotic drug toxicology in children.Antipsychotic treatment of adolescent dual diagnosis patientsClozapine for the treatment of schizophrenia.Efficacy of olanzapine in comparison with clozapine for treatment-resistant schizophrenia: evidence from a systematic review and meta-analyses.Weight gain and other metabolic adverse effects associated with atypical antipsychotic treatment of children and adolescents: a systematic review and meta-analysis.Antipsychotics in children and adolescents with schizophrenia: a systematic review and meta-analysis.Antipsychotics use in children and adolescents: An on-going challenge in clinical practice.Identification and counseling for obesity among children on psychotropic medications in ambulatory settings.Safety and efficacy of olanzapine monotherapy in treatment-resistant bipolar mania: a 12-week open-label study.
P2860
Q34322230-33238359-971E-4477-939A-2D8DA02A01B3Q34879109-22838C19-AEE0-4A24-9D72-09AD8DDAD9A3Q35128405-182119C7-A5B4-4BCE-AAE7-DD7E2F8766BEQ35136104-DB78FDCE-C674-4BE3-8432-3C7C5FE13AFBQ36186039-D68386AC-F852-466A-8161-FD3B2B3D2E86Q36997233-17BF45C5-B274-4096-AED1-04A9E4EF6D06Q37029622-BE50138C-0C04-4CEE-A4B4-F42C5EEDF28FQ37546091-6AD455C7-3B4E-42BF-B984-4207F7204487Q37852719-AA455390-690A-462B-80D2-8E4957FB4C63Q38024348-C29ED59E-8DAF-468A-B5E8-09B4B7C99B0AQ38026886-27F44F7B-84C6-4789-AAF0-77FCB9220F8CQ38068636-B1A47CE8-E41D-446F-87D2-941C76665734Q38092009-87999298-9CE7-47E6-A5F6-1856F63ED488Q38153030-C26A150E-A38E-4717-85DB-024A771D4578Q38217992-6C31D54F-C981-4674-8D58-1AF6A9BD1FA5Q44223285-B1A1F947-FA36-43EB-8412-96EFFE035F4DQ50779681-0FC66484-BDF4-4D86-947C-7F74824EA8DD
P2860
Clozapine versus "high-dose" olanzapine in refractory early-onset schizophrenia: an open-label extension study
description
2008 nî lūn-bûn
@nan
2008 թուականի Օգոստոսին հրատարակուած գիտական յօդուած
@hyw
2008 թվականի օգոստոսին հրատարակված գիտական հոդված
@hy
2008年の論文
@ja
2008年論文
@yue
2008年論文
@zh-hant
2008年論文
@zh-hk
2008年論文
@zh-mo
2008年論文
@zh-tw
2008年论文
@wuu
name
Clozapine versus "high-dose" o ...... an open-label extension study
@ast
Clozapine versus "high-dose" o ...... an open-label extension study
@en
Clozapine versus "high-dose" o ...... an open-label extension study
@nl
type
label
Clozapine versus "high-dose" o ...... an open-label extension study
@ast
Clozapine versus "high-dose" o ...... an open-label extension study
@en
Clozapine versus "high-dose" o ...... an open-label extension study
@nl
prefLabel
Clozapine versus "high-dose" o ...... an open-label extension study
@ast
Clozapine versus "high-dose" o ...... an open-label extension study
@en
Clozapine versus "high-dose" o ...... an open-label extension study
@nl
P2093
P2860
P356
P1476
Clozapine versus "high-dose" o ...... an open-label extension study
@en
P2093
Courtney DeThomas
Ginny Gerbino-Rosen
Hana M Kester
Harvey Kranzler
James Regan
Kathyrn Cullen
Sanjiv Kumra
P2860
P304
P356
10.1089/CAP.2007.0089
P50
P577
2008-08-01T00:00:00Z